Replies to post #42289 on Biotech Values

[DewDiligence]

HEB gets my vote because I have personal knowledge of the company’s dealings that I don’t have with INGN. A few years ago, HEB offered free Ampligen in return for taping an infomercial touting Ampligen as a miracle cure for various ailments. This is a level that few companies I know have stooped to.

[AlpineBV_Miller]

INGN. Roped in more people. Temerity to actually claim they had a SPA in their SEC financials when their trials started before SPA's existed. When challenged on their conference call, this is what we got (paraphrase):

Me: "Your 10-Q says you have a Special Protocol Assessment for your pivotal trials, but the SPA program started after your trials started and specifically exclude granting SPAs after a trial begins enrollment."
Nance: "Let me clarify, are you talking about the FDA's Special Protocol Assessment program?"
Me: "Yes. You claim an SPA, even using capital letters to describe it."
Nance: "We don't have an actual Special Protocol Assessment but we have gone through all the steps."

I think this was the last question or next to last question I got to ask on an INGN conference call. They "ran out of time" for the next year or two.